NASDAQ : GNLX
Genelux Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 2.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 94.11M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 93.21M |
| Enterprise Value | 76.96M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 44.81M |
| Shares Outstanding | 44.81M |
| Shares Change (YoY) | +16.39% |
| Shares Change (QoQ) | +1.83% |
| Owned by Insiders (%) | 9.27% |
| Owned by Institutions (%) | 22.62% |
| Float | 36.44M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11,651.12 |
| Forward PS | n/a |
| PB Ratio | 5.77 |
| P/TBV Ratio | 5.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 9,619.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.39 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -177.93% |
| Return on Assets (ROA) | -77.89% |
| Return on Invested Capital (ROIC) | -103.15% |
| Return on Capital Employed (ROCE) | -200.04% |
| Weighted Average Cost of Capital (WACC) | 7.24% |
| Revenue Per Employee | $308 |
| Profits Per Employee | -$1.37M |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -72.99% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 2.70 |
| Relative Strength Index (RSI) | 40.09 |
| Average Volume (20 Days) | 440,500 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.64M |
| Short Previous Month | 4.36M |
| Short % of Shares Out | 10.36% |
| Short % of Float | 12.74% |
| Short Ratio (days to cover) | 18.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 8,000 |
| Gross Profit | 8,000 |
| Operating Income | -36.42M |
| Pretax Income | -35.60M |
| Net Income | -35.60M |
| EBITDA | -36.28M |
| EBIT | -36.42M |
| Loss Per Share | -$0.86 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 18.67M |
| Total Debt | 2.42M |
| Net Cash | 16.25M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 16.11M |
| Book Value Per Share | 0.36 |
| Working Capital | 11.15M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -25.28M |
| Capital Expenditures | -3.41M |
| Depreciation & Amortization | 142,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -28.68M |
| FCF Per Share | -$0.64 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -455,275.00% |
| Pretax Margin | -444,950.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.39% |
| Shareholder Yield | -16.39% |
| Earnings Yield | -41.45% |
| FCF Yield | -30.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $18.83 |
| Price Target Difference | 805.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 2,031.99% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -11.56 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |